Myasthenia gravis following IFN-alpha-2a treatment
dc.contributor.buuauthor | Bora, İbrahim | |
dc.contributor.buuauthor | Karlı, Necdet | |
dc.contributor.buuauthor | Bakar, Mustafa | |
dc.contributor.buuauthor | Zarifoğlu, Mehmet | |
dc.contributor.buuauthor | Turan, Faruk | |
dc.contributor.buuauthor | Oǧul, Erhan | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı. | tr_TR |
dc.contributor.scopusid | 6602914249 | tr_TR |
dc.contributor.scopusid | 6506587942 | tr_TR |
dc.contributor.scopusid | 26643051200 | tr_TR |
dc.contributor.scopusid | 6603411305 | tr_TR |
dc.contributor.scopusid | 17636734100 | tr_TR |
dc.contributor.scopusid | 6603268541 | tr_TR |
dc.date.accessioned | 2021-09-13T08:43:37Z | |
dc.date.available | 2021-09-13T08:43:37Z | |
dc.date.issued | 1997 | |
dc.identifier.citation | Bora, İ. vd. (1997). "Myasthenia gravis following IFN-alpha-2a treatment". European Neurology, 38(1), 68-68. | en_US |
dc.identifier.endpage | 68 | tr_TR |
dc.identifier.issn | 0014-3022 | |
dc.identifier.issue | 1 | tr_TR |
dc.identifier.pubmed | 9252802 | tr_TR |
dc.identifier.scopus | 2-s2.0-0030786546 | tr_TR |
dc.identifier.startpage | 68 | tr_TR |
dc.identifier.uri | https://doi.org/10.1159/000112905 | |
dc.identifier.uri | https://www.karger.com/Article/Abstract/112905 | |
dc.identifier.uri | http://hdl.handle.net/11452/21882 | |
dc.identifier.volume | 38 | tr_TR |
dc.identifier.wos | A1997XL25900012 | |
dc.indexed.pubmed | Pubmed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Karger | en_US |
dc.relation.journal | European Neurology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Case report | en_US |
dc.subject.emtree | Clinical feature | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Kidney carcinoma | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Motor unit potential | en_US |
dc.subject.emtree | Myasthenia gravis | en_US |
dc.subject.emtree | Myasthenia gravis | en_US |
dc.subject.emtree | Neutropenia | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.mesh | Autoimmunity | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Interferon Alfa-2a | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Myasthenia Gravis | en_US |
dc.subject.scopus | Myasthenia Gravis; Vecuronium; Muscle Weakness | en_US |
dc.subject.wos | Clinical neurology | en_US |
dc.subject.wos | Neurosciences | en_US |
dc.title | Myasthenia gravis following IFN-alpha-2a treatment | en_US |
dc.type | Article | |
dc.wos.quartile | Q3 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: